02.19.26 -- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones

Achieve high-yield purification of complex biomolecules. This resin supports fast flow rates and scalable performance to ensure consistent recovery across your downstream bioprocessing workflows.

Learn how this platform reduces manufacturing variability. By elutriating lymphocytes from apheresis, you can provide a more consistent cell product for your downstream manufacturing stages.

Closed isolators provide the Grade A aseptic environments required for cGMP scaling. Explore how integrated automation and equipment ensure rigorous quality control for cell therapy production.

Improve accuracy and reduce stress with expert pipetting tips. Discover how technique and tool selection can boost precision and efficiency, ensuring consistent results across every lab workflow.

Buffer preparation strategies impact cost, efficiency, and risk. Compare in-house vs. outsourced approaches to help your teams align supply decisions with growth, operational needs, and long-term production goals.

TFDF-based perfusion technology can boost lentiviral vector production by 10-fold. See how this approach slashes costs and accelerates the commercialization of CAR-T and other advanced therapies.

Review best practices for evaluating risks from polymeric single-use systems. Gain the tools and insights needed to support robust assessments and maintain compliance in biomanufacturing stages.

Maximizing viral titers and full capsids requires systematic process development. Learn why choosing the right cell culture medium is foundational for optimizing AAV production in HEK 293 cells.

Gene therapy holds promise for treating various genetic diseases. Delve into the latest in gene therapy with expert insights on AAV vector integrity, dPCR-based solutions, assay design, and reference standards.

Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.

Address your concerns with traditional viral vector production processes by using a scalable upstream AAV production platform solution for viral gene therapies.